Italy Peptide Receptor Radionuclide Therapy (PRRT) Market, by Drug Type (Lutetium (Lu-177)-based, and Yttrium (Y-90)-based), by Indication (Gastroenteropancreatic Neuroendocrine Tumor), and by Distribution Channel (Hospital Pharmacies and Retail Pharmacies) - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027
Select a License Type that Suits your Business Needs
Excel Databook
US$ 2,200
Two thousand two hundred dollars
Dashboard with market estimates and forecast
Raw Data Sheet providing cross-sectional analysis
Leading Players Positioning Matrix
All segments/taxonomy covered (Statistics)
Single User License
( Full Report )
US$ 4,500
US$ 2,500
Two thousand five hundred dollars
Report accessible by 1 user only
Free 20% or 35 hours of customisation
Free post-sale service assistance
Direct access to lead analyst
Frequently purchased
Multi User License
( Full Report )
US$ 7,000
US$ 3,850
Three thousand five hundred dollars
Report accessible by 7 users
Free 30% or 70 hours of customisation
Free post-sale service assistance
Direct access to lead analysts
25% discount on your next purchase
Dedicated account manager
Personalized market brief by the lead author, if needed
Printable version of the report
Corporate User License
( Full Report )
US$ 10,000
US$ 6,000
Seven thousand five hundred dollars
Report accessible to unlimited users
Free 35% or 85 hours of customisation
Free post-sale service assistance
Direct access to lead analysts
30% discount on your next purchase
Dedicated account manager
Personalized market brief by the lead author, if needed
Italy Peptide Receptor Radionuclide Therapy (PRRT) Market, by Drug Type (Lutetium (Lu-177)-based, and Yttrium (Y-90)-based), by Indication (Gastroenteropancreatic Neuroendocrine Tumor), and by Distribution Channel (Hospital Pharmacies and Retail Pharmacies) - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027
U.S.: 
U.K. : 
AUS : 
INDIA :